Report an error   


HERDIN Record #: NCR-JRRMMC-05291205053210 Submitted: 29 May 2012 Modified: 29 May 2012

L-Ornithine, L-Aspartate (LOLA) for hepatic encephalopathy: A meta-analytic study of randomized trials.

Allan M. Romero,
Salvador A. Pineda

See More

Hepatic encephalopathy is a complex neuropsychiatric syndrome which may complicate acute or chronic live failure. It is characterized by changes in mental state including a wide range of neuropsychiatric symptoms ranging from minor signs of altered brain function to deep coma.

Treatment o hepatic encephalopathy aims at reducing the production and absorption of ammonia, which is involved in the pathogenesis. Reduction of absorption of neurotoxins from the gastrointestinal tract, low protein diet, non-absorbable disaccharides (lactulose and lactilol), and gut sterilizing antibiotics are the measures currently used in the management. Metabolic removal of ammonia through the use of L-ornithine, L-aspartate (LOLA) and benzoate have been added to the treatment regimen (J. McDonald, Evidence Based Gastroenterology and Hepatology, 1999). In cirrhotics, LOLA infusions prevented hyperammonemia after an oral protein load in a dose-dependent fashion. Benzoate, on the other hand, reacts with glycine to form hippurate, and for each mole of benzoate, one mole of waste nitrogen is excreted in the urine.

In this study, we performed a meta-analysis to assess the beneficial or harmful effects of LOLA for hepatic encephalopathy.

Publication Type
Research Report
Date

Objectives

General Objective:
To assess the beneficial or harmful effects of LOLA for hepatic encephalopathy

LocationLocation CodeAvailable FormatAvailability
Medical Library, 5/F Training and Research Office, Jose R. Reyes Memorial Medical Center Abstract Print Format
 

Copyright © One Window Project 2018. All rights reserved.